Off-Label Ketamine: What the German NVL Actually Says, and How to Assess a Service

<!-- Clinician wave 2, article 2. Audience: GPs/psychiatrists. Published PENDING per 08.10 decision. No assessments of named clinics by design. -->

A patient asks about ketamine infusions, or returns from a private consultation with a treatment plan, and the referring clinician is left to answer two questions at once: what do the guidelines actually say, and is this particular service any good. This page addresses both, for a professional audience. It is an informational summary, not clinical guidance: treatment decisions remain with you and your national guidelines. The patient-facing version is our guide to choosing a clinic; the evidence itself, with its limits, is in the ketamine evidence review.

What recommendation 7-25 says, and what it does not

The Nationale VersorgungsLeitlinie Unipolare Depression (AWMF nvl-005, chapter 7) is Germany's national care guideline for depression, and its position on racemic ketamine is unusually concrete. Recommendation 7-25 advises against the use of intravenous ketamine for depression outside an inpatient psychiatric setting (ausserhalb des stationaeren psychiatrischen Settings). The reasoning is about setting, not molecule: the guideline treats IV ketamine as an intervention whose risks (dissociation, blood pressure elevation, abuse potential, the unknowns of repeated dosing) belong in an environment with psychiatric supervision and emergency capacity.

Three boundaries keep this citation honest. First, it is a German guideline, binding on nobody outside the German care context and advisory even within it; it is not a legal prohibition in Germany or anywhere else, and a private clinic operating lawfully in Warsaw or London is not violating it, because it does not apply to them. Second, it is specific to racemic IV ketamine for depression. Esketamine nasal spray under its EU label sits in the same chapter with an open recommendation (may be considered) for the licensed indication, which is why the two routes should never be collapsed into one in a patient conversation; the practical differences are set out in Spravato vs ketamine infusions. Third, the recommendation is a statement about where, not whether: inpatient psychiatric use at the treating department's discretion is an existing practice in several European hospital systems, documented for instance by Belgium's national medicines reference for resistant depression and acute severe suicidal distress.

Off-label, legally versus clinically

Legally, off-label prescribing is ordinary medicine. Racemic ketamine is an approved anaesthetic, and a licensed physician in Germany, the UK, Poland, Spain or Switzerland may prescribe it for depression under their own professional responsibility. Nothing about the private infusion market in these countries is clandestine; in England the main providers are CQC-registered, and in Germany and Switzerland the prescribing itself is uncontroversially lawful.

Clinically, the label's absence removes three things worth naming precisely in a referral conversation. There is no approved protocol: dose, frequency, course length, maintenance schedule and co-therapy are all clinic-defined, which is why two services can describe entirely different treatments with the same word. There is no indication-specific pharmacovigilance: adverse events in off-label depression use do not flow into a structured post-marketing surveillance programme the way esketamine's do. And there is, with narrow exceptions, no public funding: the patient pays, typically 200 to 400 euros per infusion in Germany and roughly 300 to 800 pounds in England, which places the entire burden of quality assessment on the buyer.

The evidence asymmetry belongs in the same conversation. A Cochrane review supports a rapid short-term antidepressant effect, while rating much of the underlying evidence low or very low certainty; the benefit of a single infusion typically fades within one to two weeks; and the data on repeated courses, maintenance treatment and long-term safety are substantially thinner than the single-infusion literature from which clinic marketing usually generalises.

Where payers stand, and the two exceptions

Almost everywhere in Europe, off-label ketamine for depression is self-pay by definition: Germany's GKV, England's NHS (beyond small pilots), Poland's NFZ and the Swiss OKP do not fund it, and a 2023 request to add ketamine for depression to the Swiss reimbursement annex was rejected. Two exceptions are instructive precisely because of their conditions. Norway's Beslutningsforum decided in August 2025 that generic IV racemic ketamine may be used and publicly funded for treatment-resistant depression, but only in public specialist services, with written consent acknowledging off-label use, registry or study follow-up, and re-evaluation by the end of 2028. In Czechia, seven insurers partially cover ketamine-assisted psychotherapy at one Prague service. Both arrangements institutionalise exactly what the private market lacks: defined settings, mandatory follow-up, collected outcomes. When a national system does adopt off-label ketamine, it rebuilds the infrastructure of a label around it.

Assessing a service: the four domains

When a patient will proceed with or without your endorsement, the useful clinical act is often helping them tell a medical service from a dispensing operation. These are the four domains we apply across our own directory, phrased as what a referring clinician can verify in one phone call or one email. We deliberately assess no named clinics here.

Screening. Who takes the history, and is it psychiatric? A defensible service runs a physician-led assessment before any dosing decision: diagnosis confirmed, treatment history documented, contraindications actively excluded (psychotic disorders in history, uncontrolled hypertension or unstable cardiovascular disease, pregnancy, active substance use disorder). The single fastest differentiator: can a patient book a dosing session before any clinician has assessed them? If yes, it is not screening.

Monitoring. What happens during and immediately after dosing? Minimum defensible practice is blood pressure monitoring, a clinician or trained staff physically present throughout, management of dissociation as an expected effect rather than a surprise, a defined observation period before discharge, and a no-driving rule for the rest of the day. Ask what the emergency protocol is and who carries it out.

Follow-up. Is anything measured? A service that uses symptom scales (PHQ-9, MADRS or equivalent) at baseline and across the course, defines in advance what non-response looks like and what happens then, and communicates with the patient's regular psychiatrist or GP, is practising medicine. A service that sells courses of fixed length regardless of response, or whose maintenance plan is simply an open-ended subscription, has replaced follow-up with retention. Willingness to coordinate with you, the referring clinician, is itself a screening result.

Governance. Who is medically responsible, and to whom are they answerable? Verify the named medical director and their registration with the national regulator (the CQC register in England, the regional medical chamber in Germany and Poland, the cantonal authority in Switzerland); ask how adverse events are documented and where they are reported; and read the claims language. A service that promises cures, quotes response rates without sourcing them, or markets single-infusion evidence as if it covered maintenance treatment is telling you how it handles the truth. The patient-facing version of these red flags is in our choosing a clinic guide.

The referral conversation

What this adds up to for the consultation: the guideline position (7-25) is worth stating plainly, not as a prohibition but as a serious institutional judgement about setting and risk. The evidence summary that respects the patient is short-term effect supported, durability and long-term safety thin. And if the patient proceeds, the four domains above convert an unregulatable decision into an assessable one. For patients who meet the esketamine criteria, the licensed route with its defined protocol and funding pathways is usually worth exhausting first; the country-by-country criteria are in the esketamine referral guide and the full payer table on the reimbursement map. A recruiting clinical trial is the third route, free and supervised: see referring into a clinical trial.

Sources

1. NVL Unipolare Depression, AWMF nvl-005, chapter 7 (recommendation 7-25)
2. Cochrane review: ketamine and other glutamate receptor modulators for depression in adults
3. NICE NG222: Depression in adults
4. CQC register (England)
5. Nye Metoder / Beslutningsforum decision on IV ketamine, August 2025
6. CBIP: off-label intravenous ketamine as hospital practice (Belgium)